A cost comparison of warfarin vs enoxaparine or new oral anticoagulants used for the treatment of patients with pulmonary embolism


Turk M., Aldag Y., OĞUZÜLGEN İ. K. , Ekim N.

TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX, vol.64, no.3, pp.198-205, 2016 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 64 Issue: 3
  • Publication Date: 2016
  • Doi Number: 10.5578/tt.24153
  • Journal Name: TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.198-205
  • Gazi University Affiliated: Yes

Abstract

Introduction: Recently, novel oral anticoagulants (rivaroxaban, dabigatran, apixaban) have been approved for pulmonary embolism (PE) treatment. Each anticoagulant used during initial and maintenance therapy has direct and indirect costs for healthcare systems. Demonstrating the costs of treatment with different anticoagulants in a specific patient group will be helpful for clinicians determining treatment strategies.